Drug resistance in breast cancer: Mechanisms and strategies for management
Drug Resistance Updates · 2025-11 · 83 · 101288
DOI: 10.1016/j.drup.2025.101288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025-11. Verfasst von Guo-Yu Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, China; School of Pharmacy, Guangdong Pharmaceutical University, Guangz…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 506 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Guangdong Pharmaceutical University.
Abstract (Originalsprache)
Therapeutic resistance remains a significant challenge in breast cancer treatment, often driven by factors such as genetic mutations, dysregulation of receptors and signaling pathways, alterations in drug metabolism and transport, cellular heterogeneity, and modifications in the tumor microenvironment. As a highly heterogeneous and complex disease, breast cancer exhibits distinct molecular and histopathological characteristics, necessitating tailored therapeutic approaches. This article reviews recent advancements in understanding therapy resistance across four major subtypes - Luminal A, Luminal B, HER2-enriched, and triple-negative breast cancer (TNBC) - and explores potential strategies to overcome resistance, providing insights into developing novel therapeutic interventions. Notably, TNBC patients have limited treatment options, with chemotherapy remaining the standard approach and immunotherapy emerging as an adjunct strategy. We concisely overview key mechanisms contributing to therapy resistance and discuss innovative therapeutic strategies, including combination regimens, molecularly targeted therapies, photodynamic therapy, and ferroptosis-inducing treatments. Additionally, we highlight recent advancements in multi-omics data integration and artificial intelligence-driven approaches in breast cancer research. Future efforts should focus on refining predictive models, optimizing combination therapies, and leveraging artificial intelligence to enhance treatment efficacy, ultimately overcoming resistance and improving long-term outcomes for breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, China; School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China; Center for Drug Research and Development, Guangdong Pharma…
- The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, China; Laboratory of Oncology and Immunology, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, China.
- The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, China; Neurological Research Institute of Integrated Traditional Chinese and Western Medicine, First School of Clinical Medicine, The First…
- The First Affiliated Hospital, Guangdong Pharmaceutical University, Guangzhou, China.
- School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China; Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China.
- Center for Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, China; NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guan…
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangdong Pharmaceutical University
Zitieren
APA
Wu, G. Y., Xiao, M. Z., Hao, W. C., Yang, Z. S., Liu, X. R., Xu, D. S., Peng, Z. X., & Zhang, L. Y. (2025). Drug resistance in breast cancer: Mechanisms and strategies for management. Drug Resistance Updates, 83, 101288. https://doi.org/10.1016/j.drup.2025.101288
Vancouver
Wu GY, Xiao MZ, Hao WC, Yang ZS, Liu XR, Xu DS, et al. Drug resistance in breast cancer: Mechanisms and strategies for management. Drug Resistance Updates. 2025;83:101288. doi:10.1016/j.drup.2025.101288
BibTeX
@article{Wu2025,
author = {Wu, Guo-Yu and Xiao, Ming-Zhu and Hao, Wei-Chao and Yang, Zhao-Shou and Liu, Xin-Ran and Xu, Dian-Shuang and Peng, Zhong-Xing and Zhang, Lu-Yong},
title = {Drug resistance in breast cancer: Mechanisms and strategies for management},
journal = {Drug Resistance Updates},
year = {2025},
volume = {83},
pages = {101288},
doi = {10.1016/j.drup.2025.101288}
}
EUVIMED